Brought to you by 
Editas partners with Juno to create new CAR/TCR therapies
13 Nov 2019
Executive Summary
Editas Medicine Inc. and Juno Therapeutics Inc. joined forces in an exclusive collaboration that sees the partners combining Editas’ disruptive genome editing technologies with Juno’s chimeric antigen receptor (CAR) and T-cell receptor (TCR) immunotherapies to work on three new research programs in cancer.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com